Annual Report - Glenmark

More documents

Recommendations

Info

Highlights, 2004-05 Consolidated revenue and PAT The US subsidiary, Glenmark 10 Revenue 2004-05 12% 50% 13% 25% Contribution [%] Business Segments India Formulations India API Exports Formulations & API NCE increased by 60.79 percent and 159.21 percent respectively. NCE research made substantial progress with the Company's lead molecule for asthma/COPD successfully completing the Phase I clinical trials and also being outlicensed for the North American and Japanese markets. Its lead molecule for diabetes is presently in the pre-clinical testing stage. The Company incorporated a wholly-owned subsidiary in Switzerland to help manage NCE clinical trials as well as build research skills that complement R&D activities in India. Domestic formulations demonstrated a volume growth of 7.5 percent and value growth of 8.3 percent respectively. [ORG IMS MAT - Mar 2005] Construction of a new plant Pharmaceuticals Inc, USA [GPI], inaugurated its sales and marketing front-end as well as in-licensed and acquired a basket of products to commence and accelerate its operations. Glenmark has also filed 6 ANDA dossiers in FY 2005. The Company established headquarters for the UK & EU in the Thames Valley with a wholly-owned subsidiary, Glenmark Pharmaceuticals [UK] Ltd. Operations of the recently acquired company, Klinger Laboratories [Brazil], were integrated with those of Glenmark Farmacêutica Ltda. [Brazil]. The Company also acquired a leading contraceptive brand in Brazil in the last quarter of FY 2005 and added 3 more brands to its existing basket of 19 products. The newly-acquired API commenced at Baddi, Himachal Pradesh in order to meet the demands of the domestic formulations segment. manufacturing plant at Ankleshwar, Gujarat obtained US FDA approval. The Company filed 13 DMFs and Formulation exports to semiregulated markets recorded a robust growth and operations were expanded to cover around 70 semiregulated countries. 39 process patents during the year and initiated API supplies to the US market.
headed for the future Objectives, 2005-06 Achieve revenue growth of approximately 40 percent and a net profit growth of 100 percent over 2004-05. Obtain US FDA approval for the newly upgraded formulations facility in Goa. Expand capacity at current API sites and comments construction for a new plant. Strengthen presence in the semiregulated markets, especially Latin America. Register 14 ANDAs and 14 DMFs. Successfully launch and drive the growth of the eight new divisions in the domestic business. In addition, continue to launch strong molecules in the Indian formulations business and strengthen flagship brands. Projected 2005-06 20% 36% 35% 8% Contribution [%] Business Segments India Formulations 11 Annual Report 2004-2005 Accelerate the development of the front-end sales and marketing networks for selling generics in the USA. Take GRC 3886, Glenmark's lead molecule for asthma/COPD, successfully into Phase II clinical trials along with development partners and initiate Phase I trials for the diabetes lead molecule. Also take an additional PDE-4 into clinical trials for other inflammatory conditions. Commission a new formulations manufacturing facility at Baddi. Explore acquisitions in Europe and selected, less regulated markets in Latin America, Africa and Asia Pacific. India API Exports Formulations & API NCE Research
Page 1 and 2: Glenmark Pharmaceuticals Limited An
Page 3: Consolidated Financial Highlights Y
Page 6 and 7: Global. Research-focused. Integrate
Page 8 and 9: Global accounts for half the global
Page 10 and 11: Research-focused 6 In the post-GATT
Page 12 and 13: Integrated 8 Glenmark's business st
Page 16 and 17: Interview with MD & CEO 12 Glenn Sa
Page 18 and 19: Our lead compound for Asthma and CO
Page 20 and 21: Business Divisional Analysis 16 Ind
Page 22 and 23: Domestic Formulations Performance H
Page 24 and 25: 20 accounted for almost 50 percent
Page 26 and 27: Active Pharmaceutical Ingredients 2
Page 28 and 29: Therapeutic segment contribution in
Page 30 and 31: International Formulations Performa
Page 32 and 33: 28 percent evinced a growth spurt i
Page 34 and 35: Research and Development 30 JANUARY
Page 36 and 37: 32 compounds are licensed to global
Page 38 and 39: Diabetes/Obesity Incidence Globally
Page 40 and 41: Global Management Team Name Glenn S
Page 42 and 43: 38 Revenues Glenmark's turnover for
Page 44 and 45: 40 Secured Loans Secured loans incr
Page 46 and 47: existing employees to keep them in
Page 48 and 49: 44 who are geared to respond to and
Page 50 and 51: Profit & loss Account (Rs. in ‘00
Page 52 and 53: PAT Margin Research and development
Page 54 and 55: Directors’ Report Your Directors
Page 56 and 57: 52 of the Company. On exercising th
Page 58 and 59: Annexure to the Directors’ Report
Page 60 and 61: v. The products launched and sold i
Page 62 and 63: Disclosure pursuant to the provisio
Page 64 and 65:
Report on Corporate Governance Purs
Page 66 and 67:
B. Given below are the details of r
Page 68 and 69:
He is also a Director of following
Page 70 and 71:
Further resolutions with requisite
Page 72 and 73:
(All figures in Indian Rupees) Mont
Page 74 and 75:
) Risk as to fraudulent encashment
Page 76 and 77:
ANNEXURE TO AUDITORS’ REPORT Refe
Page 78 and 79:
Balance Sheet Rs. In (’000s) As a
Page 80 and 81:
Cash Flow Statement Rs. In (’000s
Page 82 and 83:
Schedules forming part of the Balan
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Schedules to the Profit & Loss Acco
Page 92 and 93:
Schedules forming part of the Finan
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
100 SECTION 212 STATEMENT PURSUANT
Page 106 and 107:
Consolidated Balance Sheet Rs. In (
Page 108 and 109:
Consolidated Cash Flow Statement Rs
Page 110 and 111:
Schedules forming part of the Conso
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
114 Notes to the Consolidated Accou
Page 120 and 121:
Notes to the Consolidated Accounts
Page 122 and 123:
118 Notes to the Consolidated Accou
Page 124:
14 13 12 43 19 71 49 10 5 20 62 3 3
show all

Annual Report - Glenmark

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?